"These allegations can impact Novartis's bottom line in a major way"
"Whether you love or hate Peter Rost (and there seems to be very little in between), you can't work in the drug or CRO industry and ignore him. Yesterday, he and Ed Silverman (Pharmalot) broke a story on a director of statistics who blew the whistle on Novartis. Of course, this caught my eye.
While I can't really determine whether Novartis is "at fault" from these two stories (and related echos throughout the pharma blogs), I can tell you about statistical reporting systems, and why I think that these allegations can impact Novartis's bottom line in a major way."
Read just how this biostatistician thinks the Novartis Whistleblower allegations can impact Novartis' bottom line. Go to Realizations in Biostatistics.